Last updated: 2026-09-07 14:32:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aura Biosciences, Inc. (AURA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $7.55, with a market capitalization of $784.01M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.73 to $9.54. This page covers its latest market performance, valuation, price trends and company information.
$784.01M | |
$7.30 | |
$26.16 | |
$4.35 | |
$7.37 | |
387.35K | |
668.30K | |
-- | |
$9.54 | |
$4.73 | |
-- | |
-- |
Aura Biosciences, Inc. (AURA) last closed at $7.37 as of 2026-09-04 23:31:00, unchanged from the previous close of $7.37.
During the latest regular trading session, AURA traded between $4.35 and $26.16, with a volume of 387.35K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Aura Biosciences, Inc. (AURA) moved from $7.70 to $7.55, representing a decline of 1.97% ($0.15).
The stock traded between $7.00 and $7.81 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 549.57 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 58.6%
AURA is currently trading at $7.55, placing it 58.6% of the way from its 52-week low of $4.73 to its 52-week high of $9.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 113 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aura Biosciences, Inc. (AURA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.